Pfizer fell 0.1% and issued less than expected profit guidance for 2026. Roku rose 3.4%, and Damo drastically raised its rating from “reduced holdings” to “increased holdings.” B. Riley Financial rose 27.4%, and second-quarter revenue surged and turned a loss into a profit. Lilly continued to rise by 0.5%, and the approval process for the diet drug orforglipron is expected to speed up significantly.

Pfizer fell 0.1% and issued less than expected profit guidance for 2026. Roku rose 3.4%, and Damo drastically raised its rating from “reduced holdings” to “increased holdings.” B. Riley Financial rose 27.4%, and second-quarter revenue surged and turned a loss into a profit. Lilly continued to rise by 0.5%, and the approval process for the diet drug orforglipron is expected to speed up significantly.